Drug sensitivity profiling identifies potential therapies for myeloid neoplasm with eosinophilia driven by a novel G3BP1-PDGFRB fusion gene.
- Resource Type
- Article
- Authors
- Wang, Jianli; Xu, Lei; Li, Yuqing; Wang, Jun; Shao, Yangliu; Lai, Weifeng; Yong, Jun; Zhao, Ling; Wei, Xuemin; Gao, Chunji; Liu, Daihong; Gao, Xiaoning; Zhang, Yongqing
- Source
- Leukemia & Lymphoma. Apr2024, Vol. 65 Issue 4, p521-525. 5p.
- Subject
- *GENE fusion
*PULMONARY eosinophilia
*EOSINOPHILIA
*CHRONIC leukemia
*B cells
- Language
- ISSN
- 1042-8194
A letter to the editor published in the journal Leukemia & Lymphoma discusses the identification of a novel G3BP1-PDGFRB fusion gene in a patient with myeloid neoplasm with eosinophilia. The fusion gene was found to be oncogenic and was not easily detected by routine cytogenetic analysis. The patient was treated with imatinib and showed a significant decrease in eosinophil count and improvement in symptoms. The study also conducted drug sensitivity profiling on both cell lines and patient-derived cells, identifying potential therapies for myeloid neoplasm with eosinophilia. The findings highlight the importance of genetic testing and personalized treatment options for this condition. [Extracted from the article]